This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound ~~Compounds~~ of ~~the~~ formula I



I

in which

R^1, R^2 are each, independently of one another, H, =O, Hal, A, ethynyl, OR^3, $N(R^3)_2$, NO_2, CN, N_3, $COOR^3$, $CON(R^3)_2$, $-[C(R^4)_2]_n$-Ar, $-[C(R^4)_2]_n$-Het, $-[C(R^4)_2]_n$-cycloalkyl, $-OCOR^3$, $-OCON(R^3)_2$, NR^3COA, or NR^3SO_2A,

R^1 and R^2 together are alternatively a bicyclically or spirocyclically bonded 3- to 7-membered carbocyclic or heterocyclic ring having from 0 to 3 N, O and/or S atoms,

R^3 is H, A, H-C≡C-CH_2-, CH_3-C≡C-CH_2-, -CH_2-CH(OH)-CH_2OH, -CH_2-CH(OH)-CH_2NH_2, -CH_2-CH(OH)-CH_2Het', $-[C(R^4)_2]_n$-Ar', $-[C(R^4)_2]_n$-Het', $-[C(R^4)_2]_n$-cycloalkyl, $-[C(R^4)_2]_n$-COOA or $-[C(R^4)_2]_nN(R^4)_2$,

R^4 is H or A,

W is N, CR^3 or an sp^2-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atom which optionally contains ~~may contain~~ a double bond,

D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or polysubstituted by Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$ or $CON(R^3)_2$,

G is $-[C(R^4)_2]_n$-, $-[C(R^4)_2]_nNR^3$-, $-[C(R^4)_2]_nO$-, $-[C(R^4)_2]_nS$- or $-[C(R^4)=C(R^4)]_n$-,

X is $-[C(R^4)_2]_nCONR^3[C(R^4)_2]_n$-, $-[C(R^4)_2]_nNR^3CO[C(R^4)_2]_n$-, $-[C(R^4)_2]_nNR^3[C(R^4)_2]_n$-, $-[C(R^4)_2]_nO[C(R^4)_2]_n$-,

$-[C(R^4)_2]_nCO[C(R^4)_2]_n-$ or $-[C(R^4)_2]_nCOO[C(R^4)_2]_n-$,

Y is alkylene, cycloalkylene, Het-diyl or Ar-diyl,

T is a monocyclic or bicyclic, saturated or unsaturated carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by =O, =S, $=NR^3$, =N-CN, $=N-NO_2$, $=NOR^3$, $=NCOR^3$, $=NCOOR^3$ or $=NOCOR^3$ and which is optionally further ~~may be furthermore be~~ monosubstituted, disubstituted or trisubstituted by R^3, Hal, A, $-[C(R^4)_2]_n$-Ar, $-[C(R^4)_2]_n$-Het, $-[C(R^4)_2]_n$-cycloalkyl, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, SO_2NR^3 and/or $S(O)_nA$,

A is unbranched or branched alkyl having 1-10 carbon atoms in which one or two CH_2 groups are each optionally ~~may be~~ replaced by O or S atoms and/or by -CH=CH- groups and/or in addition 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR^3, $N(R^3)_2$, NO_2, CN, $COOR^3$, $CON(R^3)_2$, NR^3COA, $NR^3CON(R^3)_2$, NR^3SO_2A, COR^3, $SO_2N(R^3)_2$, $S(O)_nA$, $-[C(R^4)_2]_n-COOR^3$ or $-O[C(R^4)_2]_o-COOR^3$,

Ar' is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OR^4, $N(R^4)_2$, NO_2, CN, $COOR^4$, $CON(R^4)_2$, NR^4COA, $NR^4CON(R^4)_2$, NR^4SO_2A, COR^4, $SO_2N(R^4)_2$, $S(O)_nA$, $-[C(R^4)_2]_n-COOR^4$ or $-O[C(R^4)_2]_o-COOR^4$,

Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is ~~may be~~ unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, $-[C(R^4)_2]_n$-Ar, $-[C(R^4)_2]_n$-Het', $-[C(R^4)_2]_n$-cycloalkyl, OR^3, $N(R^3)_2$, $NR^3CON(R^3)_2$, NO_2, CN, $-[C(R^4)_2]_n-COOR^3$, $-[C(R^4)_2]_n-CON(R^3)_2$, NR^3COA, NR^3SO_2A, COR^3, SO_2NR^3, $S(O)_mA$ and/or carbonyl oxygen,

Het' is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms which is ~~may be~~ unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, =S, $=N(R^4)_2$, Hal, A,

OR^4, $N(R^4)_2$, NO_2, CN, $COOR^4$, $CON(R^4)_2$, NR^4COA, $NR^4CON(R^4)_2$, NR^4SO_2A, COR^4, SO_2NR^4 and/or $S(O)_nA$,

Hal is F, Cl, Br or I,

n is 0, 1 or 2, and

o is 1, 2 or 3; [[,]]

or a and pharmaceutically usable derivative, solvate, salt, or stereoisomer ~~derivatives, solvates, salts and stereoisomers~~ thereof, including mixtures thereof in all ratios.

2. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, ~~in which~~ wherein D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or disubstituted by Hal~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

3. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, ~~in which~~ wherein D is phenyl, pyridyl, thienyl, furyl or imidazolyl, ~~each of~~ which in each case is monosubstituted or disubstituted by Hal~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

4. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein R^1 [[,]] and R^2 are each, independently of one another, H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, NHCOA, $NHSO_2A$, OCH_2COOA or OCH_2COOH~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

5. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein G is $(CH_2)_n$, $(CH_2)_nNH$-, -CH=CH- or -CH=CH-CH=CH-~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

6. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein X is -$[C(R^4)_2]_nCONR^3[C(R^4)_2]_n$-~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

7. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein X is -CONH- or -$CON(CH_2COOA)$-~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

8. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein Y is cycloalkylene, Het-diyl or Ar-diyl~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

9. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, $COOCH_3$, COOH, phenoxy or aminocarbonyl~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

10. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein T is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or $=NH_2$ and which is optionally further ~~may be~~ monosubstituted or disubstituted by Hal, A and/or OA~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

11. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein T is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, each of which is monosubstituted or disubstituted by =O or $=NH_2$ and where the radicals which is optionally further ~~may also be~~ monosubstituted or disubstituted by Hal, A and/or OA~~, and pharmaceutically usable~~

~~derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

12. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein Ar is phenyl which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2, CN, COOA, COOH or phenoxy~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

13. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms, which is unsubstituted or monosubstituted or disubstituted by Hal,

R^1 and [[,]] R^2 are each, independently of one another, H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, NHCOA, $NHSO_2A$, OCH_2COOA or OCH_2COOH, or R^1 and R^2 together are ~~alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H, A, phenyl, benzyl or $[C(R^4)_2]_nCOOA$,

R^4 is H or A,

W is N, CR^3 or an sp^2-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms, and which optionally contains ~~may contain~~ a double bond,

G is $(CH_2)_n$, $(CH_2)_nNH$-, -CH=CH- or -CH=CH-CH=CH-,

X is $-[C(R^4)_2]_nCONR^3[C(R^4)_2]_n$-,

Y is cycloalkylene, Het-diyl or Ar-diyl,

Ar is phenyl which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA, SO_2A, $COOR^2$, SO_2NH_2, CN, COOA, $COOH_2$ or phenoxy,

T is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or =NH_2 and which is optionally further ~~may be~~ monosubstituted or disubstituted by Hal, A and/or OA,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2~~;~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

14. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, ~~each of~~ which in each case is monosubstituted or disubstituted by Hal,

R^1 and [[,]] R^2 are each, independently of one another, H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, NHCOA, $NHSO_2A$, OCH_2COOA or OCH_2COOH, or R^1 and R^2 together are ~~alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H, A or CH_2COOA,

R^4 is H or A,

W is N, CR^3 or an sp^2-hybridised carbon atom,

E together with W is a 3- to 7-membered saturated carbocyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms, and which optionally contains ~~may contain~~ a double bond,

G is $(CH_2)_n$, $(CH_2)_nNH$-, -CH=CH- or -CH=CH-CH=CH-,

X is -CONH- or $-CON(CH_2COOA)$-,

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, $COOCH_3$, COOH, phenoxy or aminocarbonyl,

T is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, ~~each of~~ which in each case is monosubstituted or disubstituted by =O or =NH, and which is optionally further ~~where the radicals may also be~~ monosubstituted or disubstituted by Hal, A and/or OA,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2~~,~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

15. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl or thienyl, ~~each of~~ which in each case is monosubstituted or disubstituted by Hal,

R^1 is H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, $-OCOR^3$, NHCOA or $NHSO_2A$,

R^2 is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,

R^4 is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is $(CH_2)_n$ or $(CH_2)_nNH$-,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, ~~each of~~ which in each case is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H

atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2~~;~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

16. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl or thienyl, ~~each of~~ which in each case is monosubstituted or disubstituted by Hal,

R^1 is H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, $-OCOR^3$, NHCOA or $NHSO_2A$,

R^2 is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,

R^4 is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is $(CH_2)_n$ or $(CH_2)_nNH$-,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2~~;~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

17. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein X is -$[C(R^4)_2]_nCONR^3[C(R^4)_2]_n$- or -$[C(R^4)_2]_nCO[C(R^4)_2]_n$-~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

18. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein X is CONH or $COCH_2$~~, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

19. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,

R^1 is H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, -$OCOR^3$, NHCOA or $NHSO_2A$,

R^2 is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,

R^4 is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is $(CH_2)_n$ or $(CH_2)_nNH$-,

X is CONH or $COCH_2$,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2~~,~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

20. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,

R^1 is H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, $-OCOR^3$, NHCOA, $NHSO_2A$, $H-C\equiv C-CH_2-$, $CH_3-C\equiv C-CH_2-O-$, $-O-CH_2-CH(OH)-CH_2OH$, $-O-CH_2-CH(OH)-CH_2NH_2$ or $-O-CH_2-CH(OH)-CH_2Het'$,

R^2 is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,

R^4 is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is $(CH_2)_n$ or $(CH_2)_nNH-$,

X is CONH or $COCH_2$,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

Het' is a saturated 3-6-membered heterocyclic ring having from 1 to 3 N and/or O atoms, which is ~~may be~~ unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, A, OH, NH_2, NO_2, CN, COOA or $CONH_2$,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2~~,~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

21. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,

R^1 is ethynyl, vinyl, allyloxy, CH_3-C≡C-CH_2-O-, -O-CH_2-CH(OH)-CH_2OH, -O-CH_2-CH(OH)-CH_2NH_2 or -O-CH_2-CH(OH)-CH_2Het',

R^2 is H or OH,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,

R^4 is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is $(CH_2)_n$ or $(CH_2)_n$NH-,

X is CONH, CO, COO or $COCH_2$,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-

[2.2.2]octan-2-yl, ~~each of~~ which in each case is monosubstituted or disubstituted by carbonyl oxygen or OA,

Het' is a saturated 3-6-membered heterocyclic ring having from 1 to 3 N and/or O atoms, which is ~~may be~~ unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, A, OH, NH_2, NO_2, CN, COOA or $CONH_2$,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2~~,~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

22. (Currently Amended): A compound ~~Compounds~~ according to claim 1, ~~in which~~ wherein

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal,

R^1 is H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, NHCOA, $NHSO_2A$, OCH_2COOA or OCH_2COOH,

R^2 is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,

R^4 is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is $(CH_2)_n$, $(CH_2)_nNH$-, -CH=CH- or -CH=CH-CH=CH-,

X is CONH, $COCH_2$ or $-CON(CH_2COOA)-$,

Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene, which is unsubstituted or monosubstituted or disubstituted by A, OA, Cl, F, $COOCH_3$, COOH, phenoxy or aminocarbonyl,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,

A is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms are each optionally ~~may be~~ replaced by F,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2~~,~~

~~and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~.

23. (Currently Amended): A compound ~~Compounds~~ according to Claim 1, wherein said compound is selected from: ~~the group consisting of~~

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-piperidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-

dihydropyrrole-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-chloro-4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1λ^6-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo-1λ^6-thiazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-thiazolidine-3,4-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

N-[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[3-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxopyrazin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl isobutyrate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl propionate,

(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl]pyrrolidin-3-yl acetate,

4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-1,3-dioxolane-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,

1-N-[4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1-BOC-piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}piperazine-1,2-dicarboxamide,

1-N-[4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-oxazinane-3,4-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

6-N-[(4-chlorophenyl)]-7-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,

1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4-oxopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[2-(4-chlorophenyl)acetyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-4-hydroxypyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-1*H*-indol-3-ylmethanoyl)-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-1*H*-indol-6-ylmethanoyl)-4-hydroxypyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-4,4-difluoro-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2R,4S)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(2S,4R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-{2-[4-(2-oxo-1H-pyridin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]acetyl}pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)phenyloxycarbonyl]pyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-oxooxazolidin-5-ylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyrazin-1-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-methoxycarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-carboxy-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-bromophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{N-methoxycarbonylmethyl-N'-[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)cyclohexan-1-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-iminopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide~~, ESI 442~~;

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(2-iminopyrrolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide~~, ESI 456~~;

1-N-[(4-chlorophenyl)]-2-N-[4-{2-[(E)-cyanimino]imidazolidin-1-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide~~, ESI 468~~;

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-imino-5-methylthiazol-3-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ~~ESI 473~~;

1-N-[(4-chlorophenyl)]-2-N-{[2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ~~ESI 502~~;

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxy-2-methylpyrrolidine-1,2-dicarboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(2E,4E)-5-phenylpenta-2,4-dienyloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-methylfuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-2-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chloro-phenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1*H*-imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

N-(4-chlorophenyl)-(S)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyrrolidine-2-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((S)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)-2-phenoxyphenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-((R)-2-methyl-3-oxomorpholin-4-yl)-phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{[4-(3-oxomorpholin-4-yl)phenyl]}piperidine-1,3-dicarboxamide,

1-N-[(4-chlorophenyl)]-3-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}piperidine-1,3-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxo-1,4-oxazepan-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

24. (Currently Amended): A pyrrolidinecarboxylic ~~Pyrrolidinecarboxylic~~ acid compound ~~derivatives~~ selected fromu: ~~the group consisting of~~

1-N-[(4-chlorophenyl)]-2-N-[(1'-methyl-[1,4']bipiperidinyl-4-yl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2*H*-1,4'-bipyridinyl-4-yl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2H-1,4'-bipyridinyl-4-yl)-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-4-ylpiperazine-1-carbonyl)pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(2-methoxyphenyl)piperazine-1-carbonyl]pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-fluorophenyl)piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-hydroxy-4-(4-methoxy-phenyl)piperidine-1-carbonyl]pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-2-ylpiperazine-1-carbonyl)pyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-ethylpiperazin-1-yl)piperidine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-2-[4-(4,6-dimethylpyrimidin-2-yl)piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide,

N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(1-methylpiperidin-4-yl)piperazine-1-carbonyl]pyrrolidine-1-carboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-(2-dimethylaminoethoxy)-4-morpholin-4-ylphenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(2-ethoxy-4-morpholin-4-ylphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-[(4-morpholin-4-yl-2-propoxyphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

25. (Currently Amended): A cyclopentanecarboxylic ~~Cyclopentanecarboxylic~~ acid ~~derivatives~~ compound selected from: ~~the group consisting of~~

N-[4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)-ureido]cyclopentanecarboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chloro-phenyl)ureido]cyclopentanecarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

26. (Currently Amended): A process ~~Process~~ for the preparation of compounds of the formula I according to claim 1 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, ~~characterised in that~~ said process comprising

a) for the preparation of compounds of the formula I in which W is N and G is NH,

a compound of ~~the~~ formula II



II

in which

R^1, R^2, E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of ~~the~~ formula III

D-N=C=O III

in which

D is as defined in Claim 1,

or

b) for the preparation of compounds of ~~the~~ formula I in which X is -$[C(R^4)_2]_nCONR^3[C(R^4)_2]_n$-,

a compound of ~~the~~ formula IV

HNR^3-$[C(R^4)_2]_n$-Y-T IV

in which R^3, n, Y and T are as defined in Claim 1,

is reacted with a compound of ~~the~~ formula V



V

in which

L is Cl, Br, I or a free or reactively functionally modified OH group, and R^1, R^2, R^4, D, E, G, W and n are as defined in Claim 1,

or

c) for the preparation of compounds of ~~the~~ formula I in which W is N,

a compound of ~~the~~ formula II



II

in which

R^1, R^2, E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of ~~the~~ formula VI

D-G-CO-L VI

in which

D and G are as defined in Claim 1, and L is Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

27. Cancelled

28. Cancelled.

29. (Currently Amended): A medicament composition ~~Medicament~~ comprising at least one compound ~~of the formula I~~ according to claim 1 ~~and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,~~ and~~, if desired,~~ one ore more excipients and/or adjuvants.

30. (Currently Amended): A medicament composition ~~Medicament~~ comprising at least one compound ~~of the formula I~~ according to claim 1 ~~and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~ and at least one further medicament active ingredient.

31. (Currently Amended): A method ~~Use of compounds according to claim 1 and/or physiologically acceptable salts, salts and solvates thereof for the preparation of a medicament~~ for the treatment of a patient suffering from thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, comprising administering to said patient an effective amount of a compound according to claim1 .

32. (Currently Amended): A kit comprising ~~Set (kit) consisting of~~ separate packs of:

(a) an effective amount of a compound ~~of the formula I~~ according to claim 1 ~~and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios~~,

and

(b) an effective amount of a further medicament active ingredient.

33. (Currently Amended): A method according to claim 31, further comprising administering to said patient ~~Use of compounds of the formula I according to claim 1 one or more of Claims 1 to 23 or of compounds of Claims 24 and 25 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases, in combination with~~ at least one further medicament active ingredient.

34. (Currently Amended): An intermediate compound ~~Intermediate compounds~~ of ~~the~~ formula I-1:



I-1

in which

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, ~~each of~~ which in each case is monosubstituted or disubstituted by Hal,

R^1 is H, OH, OA, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or ethynyl,

R^2 is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

G is $(CH_2)_n$, $(CH_2)_nNH$-, -CH=CH- or -CH=CH-CH=CH-,

X is COOH,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

or an isomer or salt ~~and isomers and salts~~ thereof.

35. (Currently Amended): A compound ~~Compounds~~ according to Claim 34, wherein said compound is selected from: ~~the group consisting of~~

3-(4-chlorophenylcarbamoyl)oxazolidine-4-carboxylic acid,

3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxylic acid,

and isomers and salts thereof.

36. (Currently Amended): An intermediate compound ~~Intermediate compounds~~ selected from: ~~the group consisting of~~ tert-butoxycarbonyl

(2R,4S)- tert-butoxycarbonyl-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid,

~~(2R,4S) BOC 4 ethynyl 4 hydroxy pyrrolidine 2 carboxylic acid,~~

(2R,4R)- tert-butoxycarbonyl-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid,

~~(2R,4R) BOC 4 ethynyl 4 hydroxy pyrrolidine 2 carboxylic acid,~~

alkyl (2R,4S)- tert-butoxycarbonyl-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate wherein alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms,

~~alkyl (2R,4S) BOC 4 ethynyl 4 hydroxypyrrolidine 2 carboxylate,~~

alkyl (2R,4R)- tert-butoxycarbonyl-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate wherein alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms,

~~alkyl (2R,4R) BOC 4 ethynyl 4 hydroxypyrrolidine 2 carboxylate, where alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms,~~

and isomers and salts thereof.

37. (Currently Amended): An intermediate compound ~~Intermediate compounds~~ of the formula I-2



I-2

wherein ~~in which~~

R^1 is H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

N_3, ethynyl, vinyl, allyloxy, NHCOA, $NHSO_2A$, OCH_2COOA or OCH_2COOH,

R^2 is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^1 and R^2 together can also be ~~are alternatively~~ a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R^3 is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, ~~each of~~ which in each case is monosubstituted or disubstituted by carbonyl oxygen,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

or an isomer or salt ~~and isomers and salts~~ thereof.

38. (Currently Amended): A compound ~~Compounds~~ according to Claim 37 of ~~the~~ formula I-2a



I-2a

wherein ~~in which~~

R^1 is H, =O, $COOR^3$, OH, OA, NH_2, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3, ethynyl, vinyl, allyloxy, NHCOA, $NHSO_2A$, OCH_2COOA or OCH_2COOH,

R^2 is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R^3 is H or A,

is pyrrolidine-1,2-diyl,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-[2.2.2]octan-2-yl, ~~each of~~ which in each case is monosubstituted or disubstituted by carbonyl oxygen,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or I, and

n is 0, 1 or 2,

or an isomer or salt ~~and isomers and salts~~ thereof.

39. (Currently Amended): A compound ~~Compounds~~ according to Claim 38, wherein said compound is selected from: ~~the group consisting of~~

N-[4-(3-oxomorpholin-4-yl)phenyl]-(S)-pyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-pyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-4,4-dimethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-4-methoxypyrrolidine-2-carboxamide,

and isomers and salts thereof.

40. (Currently Amended): A medicament composition ~~Medicament~~ according to Claim 30, wherein said at least one compound is ~~comprising~~ 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or a pharmaceutically usable derivative, solvate, salt or stereoisomers ~~derivatives, solvates, salts and stereoisomers~~ thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient is aspirin.

41. (Currently Amended): A method ~~Use~~ according to Claim 33, wherein ~~comprising~~ 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivative, solvate, salt or stereoisomers ~~derivatives, solvates, salts and stereoisomers~~ thereof, including mixtures thereof in all ratios, and ~~in combination with~~ aspirin are administered to said patient.

42. (New): A compound according to claim 1, wherein

is pyrrolidine-1,2-diyl,

G is -NH-,

X is CONH,

Y is Ar-diyl,

Ar is phenyl which is substituted or unsubstituted; and

T is pyrrolidin-1-yl, is monosubstituted or disubstituted by carbonyl oxygen.